This study was a randomized double blind clinical trial. Data were collected in three stages (before the treatment, 2 weeks and 4 weeks after the treatment) and from two groups including valerian and placebo group. The subjects include 68 women between the ages of 45 to 55, who referred to health care centers in Zanjan, with a chief complaint of hot flashes and willing to be treated. The subjects were enrolled using sampling at hand and were randomly divided into two groups.
The inclusion criteria are as follows:
I. Being literate or having a literate person at home.
II. Being a menopausal woman between the ages of 45 and 55.
III. Elapse of at least one and at most 5 years after menopause.
IV. Not having known physical or mental diseases.
V. Not using relaxation techniques and hormonal or herbal therapies.
VI. Not using cigarette and alcohol.
VII. Not having stressors during the past 6 months.
VIII. Not having a family history of estrogen-related cancer.
Before entering the study, all subjects were given information about the research methodology and entered the project after signing the informed written consent form. They were also asked to record any problems like headache, nausea, gastrointestinal disorders, anorexia and any other problem during both stages of treatment in special forms. Severe symptoms had to be reported to the researcher.
Subject using special medications, having mental, endocrine and gynecological disorders, or being treated with hormone replacement therapy, experiencing abnormal menopause caused by irradiation and being allergic to Valerian were excluded from the study.
Data were collected using questionnaires filled by the researcher and two other information forms. At first, questionnaire number 1 (
Table 1) was filled with information about demographics, obstetrics history and questions about doing sports, severity of hot flashes and the manner they were treated. Then, during the two weeks before treatment, information forms (1 and 2) were filled with study diet, frequency and severity of hot flashes. Reliability and validity of questionnaires were approved by content validity and re-tested with the correlation of 90%.
Valerian was purchased as bulk from Zardband Company, validated by one of the authors (Dr. Mojab). Afterward, valerian was ground, and then filled in capsules using an automatic capsule filling machine. The placebo was made using the same machine but capsules were filled with potato starch.
| Treatment Categories
|
|---|
| Variable | Valerian | Placebo |
|---|
| Age | 51.2 ± 2.6 | 51.7 ± 2.9 |
| Age at menarch | 13.17 ± 1.34 | 13.30 ± 1.06 |
| Age at menopause | 49.30 ± 3.01 | 48.90 ± 2.72 |
| BMI | 28.54 ± 3.01 | 27.8 ± 3.82 |
Capsules containing 225 mg of valerian root were prescribed 3 times a day for eight weeks for the case group. The placebo group received the same dosage of the placebo. Encoded capsules were given to the subjects in both groups in similar packages. Neither the patients nor the researchers were aware of the assigned groups.
Information forms (1 and 2) were given to research centers and received by subjects from two weeks before the program until the end of the study in order to determine the severity and frequency of hot flashes and daily meals. The data were collected and analyzed at the end of each week.
SPSS version 16 was used for data analysis in this study. Descriptive statistics including distribution tables, mean and standard deviation were used to describe subjects’ characteristics. As the response variable was graded and data were not natural, at first, the severity of hot flashes was compared in 3 cycles using the Friedman test. Then, responses between the two groups were compared using Man-Whitney test. Once Freidman test was meaningful, treatment cycles were two by two compared using corrected Alpha and Wilcoxon test.